Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336188 · ClinicalTrials.gov registry record · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
A Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging, sponsored by University of Arkansas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
- 1
- Study location
NCT05336188: Recruiting Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging, sponsored by University of Arkansas.
NCT05336188 is a Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 255 participants, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05336188, a Phase 2 study of Opioid-Related Disorders and Magnetic Resonance Imaging, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to standard app-based self-monitoring of drug use and personalized feedback, project innovation is enhanced by the proposed use of location-tracking technology for targeted, personalized intervention when participants enter self-identified areas of high risk for relapse. Furthermore, the proposed sub-study would use longitudinal functional neuroimaging to elucidate the brain-cognition relationships underlying individual differences in treatment outcomes, offering broad significance for understanding and enhancing the efficacy of this and other app-based interventions.
Conditions Studied
Interventions
- DEVICE Smartphone
Study Locations (1)
Arkansas
- Brain Imaging Research Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
What NCT05336188 shows while recruiting
NCT05336188 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, below the 342-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (25% lower).
The record links to 7 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Smartphone is the first listed.
NCT05336188 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT05336188 about?
NCT05336188 is a clinical study titled "Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder". The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to standard app-based self...
What is the current status of trial NCT05336188?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2023-05-16. Estimated completion is 2028-09-30.
What conditions does trial NCT05336188 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Magnetic Resonance Imaging, Craving, Opiate Substitution Treatment, Mobile Applications.
What interventions are being tested in trial NCT05336188?
The interventions under investigation include: Smartphone (DEVICE).
Who is sponsoring clinical trial NCT05336188?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336188 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05336188's enrollment target sits among peer trials
255 14th of 47 higher than 34 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
- NCT05616130 · 255 participants
Pathological Myeloid Activation After Sepsis and Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI